Welcome to the international HTA database

Showing [21959 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2017	NIHR Health Services and Delivery Research programme	Cross-national mixed-methods comparative case study of recovery-focused mental health care planning and co-ordination in acute inpatient mental health settings (COCAPP-A)
2017	Agency for Healthcare Research and Quality (AHRQ)	First- and second-generation antipsychotics in children and young adults: systematic review update
2017	NIHR Health Services and Delivery Research programme	Investigating the organisational factors associated with variation in clinical productivity in community pharmacies: a mixed-methods study
2017	Canadian Agency for Drugs and Technologies in Health (CADTH)	Dialysis modalities for the treatment of end-stage kidney disease: a health technology assessment
2017	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Care needs assessment tools]
2017	Agency for Healthcare Research and Quality (AHRQ)	Interventions to prevent age-related cognitive decline, mild cognitive impairment, and clinical Alzheimer's-type dementia
2017	NIHR Health Services and Delivery Research programme	Quality and reporting standards, resources, training materials and information for realist evaluation: the RAMESES II project
2017	Agency for Healthcare Research and Quality (AHRQ)	Preventing complications and treating symptoms of diabetic peripheral neuropathy
2017	NIHR Health Services and Delivery Research programme	Optimal NHS service delivery to care homes: a realist evaluation of the features and mechanisms that support effective working for the continuing care of older people in residential settings
2017	NIHR Health Technology Assessment programme	Randomised controlled trial and economic analysis of an internet-based weight management programme: POWeR+ (Positive Online Weight Reduction)
2017	Agency for Healthcare Research and Quality (AHRQ)	Assessment tools for palliative care
2017	NIHR Health Services and Delivery Research programme	Variations in mortality across the week following emergency admission to hospital: linked retrospective observational analyses of hospital episode data in England, 2004/5 to 2013/14
2017	Agency for Healthcare Research and Quality (AHRQ)	Treatment of osteoarthritis of the knee: an update review
2017	NIHR Public Health Research (PHR) programme	Assessing the impact and cost-effectiveness of needle/syringe provision and opiate substitution therapy on hepatitis C transmission among people who inject drugs in the United Kingdom: analysis of pooled datasets and economic modelling
2017	NIHR Health Technology Assessment programme	Timing of surgical intervention for developmental dysplasia of the hip: a randomised controlled trial (Hip 'Op)
2017	Agency for Healthcare Research and Quality (AHRQ)	Tympanostomy tubes in children with otitis media
2017	NIHR Public Health Research (PHR) programme	Adapting the ASSIST model of informal peer-led intervention delivery to the Talk to FRANK drug prevention programme in UK secondary schools (ASSIST + FRANK): intervention development, refinement and a pilot cluster randomised controlled trial
2017	NIHR Public Health Research (PHR) programme	Results of the First Steps study: a randomised controlled trial and economic evaluation of the Group Family Nurse Partnership (gFNP) programme compared with usual care in improving outcomes for high-risk mothers and their children and preventing abuse
2017	NIHR Health Technology Assessment programme	CollAborative care and active surveillance for Screen-Positive EldeRs with subthreshold depression (CASPER): a multicentred randomised controlled trial of clinical effectiveness and cost-effectiveness
2017	NIHR Public Health Research (PHR) programme	Could scale-up of parenting programmes improve child disruptive behaviour and reduce social inequalities? Using individual participant data meta-analysis to establish for whom programmes are effective and cost-effective
2017	NIHR Health Technology Assessment programme	Accessibility and implementation in the UK NHS services of an effective depression relapse prevention programme: learning from mindfulness-based cognitive therapy through a mixed-methods study
2017	Belgian Health Care Knowledge Centre (KCE)	Bevacizumab in the treatment of ovarian cancer
2018	NIHR Health Technology Assessment programme	Behavioural activation versus guided self-help for depression in adults with learning disabilities: the BeatIt RCT
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Immunoglobulin for myasthenia gravis chronic treatment]
2018	Canary Health Service	[SEEKER System for the screening of lysosomal storage diseases]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Guselkumab (plaque psoriasis) - Addendum to Commission A17-60]
2018	NIHR Health Technology Assessment programme	Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: systematic reviews and economic evaluation
2018	Penn Medicine Center for Evidence-based Practice (CEP)	Update: Best practices for central venous catheter removal
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[PET/CT scan for solitary pulmonary nodule and non-small cell lung cancer]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Targeted lung denervation using catheter ablation for chronic obstructive pulmonary disease - Addendum to Commission H16-01]
2018	NIHR Health Technology Assessment programme	Pharmacological and non-pharmacological interventions for non-respiratory sleep disturbance in children with neurodisabilities: a systematic review
2018	Penn Medicine Center for Evidence-based Practice (CEP)	Point-of Care Ultrasound for Acute Respiratory Distress
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[LDL-Apheresis in familial hypercholesterolemia and hypertriglyceridemia]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Non-invasive prenatal testing to determine the risk of autosomal trisomies 13, 18 and 21 in high-risk pregnancies]
2018	NIHR Health Technology Assessment programme	Brain and spinal stimulation therapies for phantom limb pain: a systematic review
2018	Penn Medicine Center for Evidence-based Practice (CEP)	Monitoring of Anticoagulation in Patients on Extracorporeal Membrane Oxygenation
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge on organizational models for intensive care units]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Abemaciclib, palbociclib and ribociclib in breast cancer]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sonidegib (basal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2018	NIHR Health Technology Assessment programme	Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews
2018	Penn Medicine Center for Evidence-based Practice (CEP)	Transjugular Intrahepatic Portosystemic Shunts for Patients with Acute Variceal Bleeding
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guidelines and standards, English version updated in June 2020: requirements relating to the institutions responsible for the operation of acute healthcare facilities designated within the Quebec trauma network]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[T2 mapping for articular cartilage assessment]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Benralizumab (asthma) - Benefit assessment according to §35a Social Code Book V]
2018	NIHR Health Technology Assessment programme	Bariatric surgery, lifestyle interventions and orlistat for severe obesity: the REBALANCE mixed-methods systematic review and economic evaluation
2018	Penn Medicine Center for Evidence-based Practice (CEP)	Update: Anticoagulation Management in Paracentesis and Thoracentesis
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Pyridostigmine with aminopyridines in myasthenia gravis or Lambert-Eaton myasthenic syndrome]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V]
2018	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	Treatment Foster Care Oregon for seriously delinquent adolescents
2018	NIHR Health Technology Assessment programme	Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation
2018	Penn Medicine Center for Evidence-based Practice (CEP)	Home Administration of Intravenous Immunoglobulin
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: best practices for runaway prevention and intervention for youths living in rehabilitation centres for young persons with adjustment problems]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Natalizumab for recurrent-remitting and JC virus seropositive multiple sclerosis]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Letermovir (prophylaxis of cytomegalovirus reactivation and disease) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018	NIHR Health Technology Assessment programme	Contrast-enhanced ultrasound and/or colour duplex ultrasound for surveillance after endovascular abdominal aortic aneurysm repair: a systematic review and economic evaluation
2018	Penn Medicine Center for Evidence-based Practice (CEP)	Using Patient Generated Health Data in an Electronic Health Record
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: national and international practices in the organization of rehabilitative care for adults with permanent or temporary motor disabilities]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Abiraterone acetate (prostate cancer) - Addendum to Commission A17-64]
2018	Penn Medicine Center for Evidence-based Practice (CEP)	Management of Post-Biopsy Renal Bleeding
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Motor-driven continuous passive motion (CPM) devices after interventions on the knee and shoulder joint]
2018	Penn Medicine Center for Evidence-based Practice (CEP)	Location of Implanted Ports for Chemotherapy
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Glycerol phenylbutyrate (urea-cycle disorders) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018	Penn Medicine Center for Evidence-based Practice (CEP)	Best Practices for Treating Acute/Severe Hyperkalemia in the Hospital Setting
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: living environment quality in long-term care facilities for dependent seniors]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ixekizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2018	Penn Medicine Center for Evidence-based Practice (CEP)	Guidelines for Electrocardiography on Arrival to the Emergency Department
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: regulation of private congregate living facilities for the elderly]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fluticasone furoate/umeclidinium/vilanterol (COPD) - Benefit assessment according to §35a Social Code Book V]
2018	Penn Medicine Center for Evidence-based Practice (CEP)	Guidelines for Management of Acute Hydronephrosis
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: ministerial standards of access, quality, continuity, efficiency and effectiveness of the service d’intervention de crise dans le milieu 24/7]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Insulin glargine/lixisenatide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Alectinib (non-small-cell lung cancer) - Addendum to Commission A17-67]
2018	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Diagnostic effectiveness and safety of elastography in liver fibrosis]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Support for the development of an S3 guideline on natural childbirth - Evidence reports]
2018	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Analysis of the efficacy and safety of orthodontic-orthopedic maxillary expansion devices as an alternative to adenotonsillectomy and/or pharmacological treatment in the management of sleep apnea-hypopnea syndrome in pediatric patients]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evolocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brentuximab vedotin (cutaneous T-cell lymphoma) - Addendum to Commission G18-01]
2018	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Dropouts in Psychotherapy. Part I: Predictors, theories and models to explain and recommend courses of action to avoid discontinuation of therapy. Part II: "Overview of Reviews" on dropouts in psychotherapy
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[Optimal use guide: herpes simplex eye disease]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Argon plasma coagulation for gastrointestinal lesions]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Investigation of the statistical properties of methods for the applicability of study results to subpopulations]
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[Optimal use guide: blepharitis]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Procalcitonin-guided antibiotic therapy for acute infections]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Patiromer (hyperkalaemia) - Benefit assessment according to §35a Social Code Book V]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Venetoclax for relapsed or refractory chronic lymphocytic leukemia]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Glycopyrronium bromide (sialorrhoea) - Benefit assessment according to §35a Social Code Book V]
2018	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Options to identify inappropriate use of MRI, Part 3
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Trastuzumab emtansine for breast cancer]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bezlotoxumab (Clostridium difficile infection) - Benefit assessment according to §35a Social Code Book V]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Stereotactic body radiotherapy in liver tumors]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: islet transplantation in patients with unstable type I diabetes]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Stereotactic body radiotherapy for prostate cancer]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lumacaftor/ivacaftor (cystic fibrosis) - Addendum to Commission A18-08]
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: portrait of opioid use in persons covered by Québec’s public prescription drug insurance plan]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Continuous subcutaneous infusion pump for diabetic patients]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Burosumab (X-linked hypophosphataemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ocrelizumab (multiple sclerosis) - Addendum to Commission A18-06]
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: the use of EndoPredict and Prosigna for early invasive breast cancer]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Stereotactic body radiotherapy for lung cancer]